Cadrenal Therapeutics Inc.

Company Overview

Business Model: Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on advancing novel therapies for life-threatening immune and thrombotic conditions. Following the acquisition of a 12-lipoxygenase ("12-LOX") platform of assets in December 2025, the company transitioned its primary strategic focus to the development of CAD-1005 for immune-mediated and thrombotic disorders. Its lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia ("HIT"). The broader pipeline includes tecarfarin, an oral vitamin K antagonist ("VKA") for chronic anticoagulation in patients with kidney dysfunction or left ventricular assist devices ("LVADs"), and frunexian, a Phase 2-ready intravenous ("IV") Factor XIa inhibitor for acute care settings.

Market Position: Cadrenal Therapeutics, Inc. positions CAD-1005 as a first-in-class selective 12-LOX inhibitor, currently the only one in clinical-stage development, addressing the underlying pathophysiology of HIT. Tecarfarin is designed to offer a more reliable alternative to warfarin for patients with complex needs, holding Orphan Drug Designation ("ODD") and Fast Track designation from the FDA for specific indications. Frunexian is highlighted as the only IV Factor XIa inhibitor in clinical development exclusively targeting acute/critical care hospital settings. The company estimates the peak annual market revenue potential for CAD-1005 in HIT at approximately $825 million, and a combined peak annual U.S. market revenue potential of approximately $2 billion for tecarfarin and frunexian in orphan and high-risk cardiovascular conditions. The company faces substantial competition from major pharmaceutical and biotechnology companies with greater resources and established products in the broader anticoagulant market.

Recent Strategic Developments:

• Veralox Asset Purchase (December 10, 2025): Cadrenal Therapeutics, Inc. acquired all rights to CAD-1005 (formerly VLX-1005) and the CAD-2000 series from Veralox Therapeutics Inc. for a cash payment of $200,000, assumed liabilities, contingent milestone payments up to $15 million, and 5% royalties on net sales. This acquisition included an exclusive worldwide license agreement with Old Dominion University for 12-LOX.
• End-of-Phase 2 ("EOP2") Meeting with FDA (March 26, 2026): The company completed its EOP2 meeting with the FDA, clarifying a potential registrational path for its planned Phase 3 pivotal trial of CAD-1005 in patients with HIT.
• eXIthera Purchase Agreement (September 12, 2025): Cadrenal Therapeutics, Inc. acquired assets, including frunexian (EP-7041) and EP-7327, intellectual property, and clinical data from eXIthera Pharmaceuticals, Inc. The purchase price included $50,000 in transaction closing costs, assumed liabilities, contingent milestone payments up to $15 million, and 2% royalties on net sales (outside China) plus 50% of royalties from Sichuan Haisco Pharmaceutical Co., Ltd.
• Collaboration Agreement with Abbott Global Enterprises Limited (March 2025): The company signed an agreement with Abbott Global Enterprises Limited to support the development of tecarfarin in patients with an implanted HeartMate 3 LVAD, providing insights and support for trial design, site identification, and HeartMate expertise.
• Tecarfarin Manufacturing: Recently completed the manufacturing of tecarfarin drug product in accordance with current good manufacturing practices ("cGMP").

Geographic Footprint: Cadrenal Therapeutics, Inc.'s corporate headquarters are located in Ponte Vedra, Florida, U.S. While its primary focus is the U.S. market, certain material suppliers and manufacturing sites for its product candidates are located outside the U.S. The company holds an exclusive license agreement for frunexian in the Chinese market with Sichuan Haisco Pharmaceutical Co., Ltd. Additionally, CAD-1005 has received orphan designation from the European Medicines Agency ("EMA"). The company intends to commercialize its product candidates in selected foreign markets through collaborations with third parties.

Financial Performance

Revenue Analysis

Cadrenal Therapeutics, Inc. has not generated any revenue from operations for the fiscal years ended December 31, 2025, and 2024.

Profitability Metrics:

• Gross Margin: N/A
• Operating Margin: N/A
• Net Margin: N/A

Investment in Growth:

• R&D Expenditure: $4.1 million (2025), $4.2 million (2024).
• Capital Expenditures: $5,104 (2025), $6,537 (2024).
• Strategic Investments: In 2025, the company expensed approximately $0.5 million in in-process research and development ("IPR&D") costs related to asset purchase agreements. This includes $331,797 for the Veralox Assets (CAD-1005) and $201,216 for the eXIthera Assets (frunexian). These amounts represent initial cash payments and direct transaction costs, with additional contingent milestone payments up to $15 million for each acquisition.

Product Pipeline Analysis

Cadrenal Therapeutics, Inc. manages its business activities as a single entity and operates in one reportable segment. The following details its key product candidates.

CAD-1005

Financial Performance:

• Revenue: Not applicable (no product revenue).
• Operating Margin: Not applicable (no product revenue).
• Key Growth Drivers: CAD-1005 is a first-in-class selective 12-LOX inhibitor, designed to directly address the immune-mediated, platelet-centric pathophysiology of HIT. It has received Orphan Drug Designation from the FDA for prophylaxis of thrombosis in HIT patients, FDA Fast Track designation for the treatment and prevention of HIT, and orphan designation from the EMA for the treatment of platelet-activating factor 4 disorders. The company has clarified a potential registrational path for a planned Phase 3 pivotal trial in HIT following an EOP2 meeting with the FDA.

Product Portfolio:

• Major product lines: CAD-1005 (lead product candidate).
• New product launches or major updates: The 12-LOX portfolio includes parenteral (injectable) and oral second-generation candidates (CAD-2000 series) in early development for chronic conditions such as diabetes, atherosclerosis, chronic vascular inflammation, and hyper-inflammatory responses.

Market Dynamics:

• Competitive positioning within segment: CAD-1005 is currently the only selective 12-LOX inhibitor in clinical-stage development. It competes with existing non-heparin anticoagulants like direct thrombin antagonists (bivalirudin and argatroban), fondaparinux (a direct Xa antagonist), and direct oral anticoagulants ("DOACs").
• Key customer types and market trends: Targets patients with HIT, a serious, life-threatening prothrombotic complication of heparin administration. The estimated peak annual market revenue potential for CAD-1005 in HIT is approximately $825 million.

Tecarfarin

Financial Performance:

• Revenue: Not applicable (no product revenue).
• Operating Margin: Not applicable (no product revenue).
• Key Growth Drivers: Tecarfarin is a novel late-stage, reversible VKA designed as a warfarin replacement for patients with complex needs, specifically for chronic use in patients with kidney dysfunction or LVADs. It is designed to overcome metabolic factors that make warfarin less reliable by utilizing the human carboxylesterase 2 ("CES2") pathway, avoiding CYP450 metabolism. Tecarfarin has ODD and Fast Track designation from the FDA for prevention of systemic thromboembolism in patients with end-stage kidney disease ("ESKD") and atrial fibrillation ("AFib"), and ODD for prevention of thrombosis and thromboembolism in patients with implanted mechanical circulatory support devices (including LVADs). A collaboration agreement with Abbott Global Enterprises Limited supports its development in HeartMate 3 LVAD patients.

Product Portfolio:

• Major product lines: Oral vitamin K antagonist.
• New product launches or major updates: Recently completed manufacturing of tecarfarin drug product in accordance with cGMP. Evaluating opportunities for additional Phase 2/3 trials for ESKD patients with AFib and/or stable LVAD patients.

Market Dynamics:

• Competitive positioning within segment: Tecarfarin aims to address unmet medical needs in patient populations where warfarin is the standard of care but has limitations, and DOACs are contraindicated or not recommended. It competes primarily with warfarin and DOACs such as Pradaxa, Xarelto, Eliquis, and Savaysa.
• Key customer types and market trends: Targets patients with ESKD and AFib (approximately 145,000 ESKD patients also have AFib in the U.S.) and patients with LVADs. The estimated combined peak annual U.S. market revenue potential for tecarfarin and frunexian in orphan and high-risk cardiovascular conditions is approximately $2 billion.

Frunexian

Financial Performance:

• Revenue: Not applicable (no product revenue).
• Operating Margin: Not applicable (no product revenue).
• Key Growth Drivers: Frunexian is a first-in-class, Phase 2-ready IV Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces is significant. It is the only IV FXIa inhibitor in clinical development exclusively targeting the acute/critical care hospital setting. Preclinical and Phase 1 data indicate it inhibits thrombosis while minimizing bleeding risk, with rapid onset of action, predictable effect on coagulation, short pharmacodynamic half-life, and apparent lack of dependence on renal clearance mechanisms.

Product Portfolio:

• Major product lines: Frunexian (EP-7041) as an IV Factor XIa inhibitor.
• New product launches or major updates: The acquired portfolio also includes EP-7327 and other compounds, including oral Factor XIa inhibitors.

Market Dynamics:

• Competitive positioning within segment: Frunexian is the only parenteral XIa antagonist currently being evaluated for acute care applications. It competes with widely used inpatient parenteral anticoagulants such as unfractionated heparin, low molecular weight ("LMW") heparin, direct thrombin antagonists (bivalirudin and argatroban), and direct Xa inhibitors (fondaparinux).
• Key customer types and market trends: Targets patients in acute/critical care hospital settings. The estimated combined peak annual U.S. market revenue potential for frunexian and tecarfarin in orphan and high-risk cardiovascular conditions is approximately $2 billion.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not mentioned in the filing.
• Dividend Payments: Cadrenal Therapeutics, Inc. has never declared or paid any cash dividends on its Common Stock and does not anticipate paying any in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not mentioned in the filing.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $4.0 million (compared to $10.0 million as of December 31, 2024).
• Total Debt: Not explicitly stated, but no long-term debt is visible in the balance sheet. The company may incur other indebtedness for future financing.
• Net Cash Position: $4.0 million.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not disclosed.

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(12.6) million (cash used in operating activities).
• Free Cash Flow: Approximately $(12.6) million (Operating Cash Flow less Capital Expenditures).
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Cadrenal Therapeutics, Inc. does not possess its own manufacturing infrastructure and does not intend to develop one. The company relies on third-party pharmaceutical contract development and manufacturing organizations ("CDMOs") for the development of validated processes and the supply of active pharmaceutical ingredients and clinical trial material. While these CDMOs have the capability to scale up for commercial production of tecarfarin, the company has not entered into any long-term supply agreements or commercialization partnerships with these vendors. For CAD-1005 and frunexian, the company intends to execute contracts with third-party CDMOs for drug substance and drug product supply, but these contracts are not yet in place.

Supply Chain Architecture: Key Suppliers & Partners:

• CDMOs: Third-party pharmaceutical contract development and manufacturing organizations for active pharmaceutical ingredients and clinical trial materials.
• Third-party vendors: Supply materials such as reagents and containers to CDMOs.
• Old Dominion University: Licensor of the exclusive worldwide license for 12-LOX (CAD-1005).
• Sichuan Haisco Pharmaceutical Co., Ltd.: Licensee for the development and commercialization of frunexian in the Chinese market.
• Abbott Global Enterprises Limited: Collaboration partner supporting the development of tecarfarin in patients with implanted HeartMate 3 LVADs.

Facility Network:

• Corporate Headquarters: 822 A1A North, Suite 306, Ponte Vedra, Florida 32082. This office space is leased under a 12-month term, expiring October 31, 2026, with a monthly rent of $2,346.
• Manufacturing: Relies on third-party CDMOs, with certain sites located outside of the U.S.
• Research & Development: R&D activities are conducted, but specific dedicated facilities are not detailed.

Operational Metrics: Operational metrics such as capacity utilization, efficiency measures, or quality indicators are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: If product candidates receive FDA or other regulatory approvals, Cadrenal Therapeutics, Inc. plans to commercialize its products by hiring and training a small, dedicated salesforce for the U.S. market and potentially other major markets.
• Channel Partners: The company anticipates entering into various distribution agreements and commercial partnerships in territories where it does not establish an internal sales force, including international markets.
• Digital Platforms: Not explicitly mentioned as a primary distribution channel.

Customer Portfolio: Enterprise Customers:

• Strategic Partnerships: Abbott Global Enterprises Limited is a strategic partner supporting the development of tecarfarin.
• Customer Concentration: Not explicitly disclosed in the filing.

Geographic Revenue Distribution:

• Cadrenal Therapeutics, Inc. currently generates no revenue.
• Future profitability is expected to depend, in part, on its ability to commercialize product candidates in foreign markets, which will involve collaborations with third parties.
• Sichuan Haisco Pharmaceutical Co., Ltd. holds an exclusive license for frunexian in China.
• CAD-1005 has received orphan designation from the EMA, indicating potential market access in the European Union.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry, particularly in new drug development, is highly competitive, involving major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies globally. Cardiovascular drug development has experienced stagnated investment over the past two decades, partly due to the high cost of conducting clinical outcome trials that require clinically meaningful cardiovascular endpoints. Competitors often possess substantially greater financial, research and development, testing, and marketing resources, as well as more extensive experience in developing and commercializing pharmaceuticals. Industry consolidation can further concentrate resources among fewer competitors.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• CAD-1005: Competes with existing non-heparin anticoagulants, including direct thrombin antagonists (bivalirudin and argatroban), fondaparinux (a direct Xa antagonist), and DOACs.
• Tecarfarin: Faces substantial competition primarily from warfarin (a generic, widely used VKA) and DOACs such as Pradaxa (Boehringer Ingelheim), Xarelto (Janssen Pharmaceuticals), Eliquis (Bristol Myers Squibb), and Savaysa (Daiichi Sankyo).
• Frunexian: Competes with widely used inpatient parenteral anticoagulants, including unfractionated heparin, LMW heparin, direct thrombin antagonists (bivalirudin and argatroban), and direct Xa inhibitors (fondaparinux).

Emerging Competitive Threats: The company acknowledges that other entities, including academic institutions, government agencies, and other research organizations, may develop new products or alternative technologies. Competitors may pursue alternative pathways or more effective 12-LOX candidates, potentially rendering Cadrenal Therapeutics, Inc.'s platform obsolete.

Competitive Response Strategy: Cadrenal Therapeutics, Inc.'s strategy involves advancing novel, first-in-class therapies that address significant unmet medical needs. This includes leveraging regulatory designations like ODD and Fast Track, and forming strategic collaborations, such as with Abbott Global Enterprises Limited. The company also relies on obtaining and maintaining robust intellectual property protection for its drug candidates.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Acceptance: Risk that product candidates may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors, impacting commercial success.
• Competition: Substantial competition from major pharmaceutical companies with significantly greater resources, established products, and extensive experience in drug development and marketing.
• Pricing Pressure: Exposure to cost-containment initiatives from government and private insurers, including legislative changes like the Inflation Reduction Act of 2022, which could reduce pricing flexibility and reimbursement rates.
• Global Health Crises: Potential for delays in patient enrollment, disruptions to clinical development timelines, increased operational costs, and supply chain interruptions due to pandemics or other health crises.
• Technology Disruption: Risk that competitors may develop alternative pathways or more effective candidates, potentially rendering the company's platform of assets obsolete.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on third-party CDMOs for manufacturing active pharmaceutical ingredients and clinical trial materials, without long-term supply agreements for CAD-1005 or frunexian. Limited number of suppliers for certain materials.
• Geographic Concentration: Dependence on manufacturing sites and material suppliers located outside the U.S., exposing the company to international trade and regulatory risks.
• Capacity Constraints: Risk that CDMOs may not have sufficient capacity or scalability to meet commercial production demands if products are approved.
• Regulatory Compliance: CDMOs must comply with cGMP requirements; any failure to comply could lead to delays, sanctions, or supply disruptions.

Clinical Trial Risks:

• Trial Delays/Failure: Clinical trials are expensive, time-consuming, and inherently uncertain. Risks include unforeseen safety issues, failure to determine appropriate dosing, inability to demonstrate effectiveness, slower-than-expected patient enrollment, and subject drop-outs.
• Third-Party Reliance: Heavy reliance on contract research organizations ("CROs") and other third parties to conduct clinical trials, with limited direct control over their operations and resource allocation.
• Data Integrity: Uncertainty regarding the accuracy and sufficiency of historical clinical data from trials conducted by third parties prior to the company's ownership of the assets.
• Regulatory Approval: Risk of not receiving regulatory approval, or receiving approval with significant restrictions (e.g., limited indications, Risk Evaluation and Mitigation Strategies ("REMS"), boxed warnings), which could impair commercial viability.
• Post-Approval Requirements: Ongoing regulatory obligations, including post-market surveillance, cGMP compliance, and potential requirements for costly post-approval (Phase 4) clinical trials.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern: The company has a history of operating losses and negative cash flows, with existing cash resources insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Need for Capital: Requires substantial additional financing (equity offerings, debt financings, strategic partnerships) to fund planned clinical trials and commercialization efforts, with risks of dilution for existing stockholders or unfavorable terms.
• Inflation: Increased inflation rates could lead to higher operating costs and reduced liquidity.

Regulatory & Compliance Risks:

• Government Regulation: Extensive and evolving regulatory landscape by the FDA and other authorities covering all stages of drug development and commercialization.
• Trade Laws: Exposure to U.S. and foreign anti-corruption, anti-money laundering, export control, and sanctions laws, with potential for substantial penalties for non-compliance.
• Healthcare Fraud & Abuse: Risk of civil or criminal penalties for non-compliance with federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act) related to marketing and sales practices.
• Government Shutdowns: Inadequate funding or disruptions at federal agencies (FDA, SEC) could delay regulatory reviews, impact access to capital markets, and hinder business operations.
• AI Use: Operational, regulatory, ethical, and reputational risks associated with the increasing reliance on artificial intelligence ("AI") in research, development, and commercial activities, including unpredictable or biased outputs, data integrity issues, and evolving regulatory scrutiny.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Operational exposure due to reliance on foreign manufacturing sites and potential commercialization in international markets.
• Trade Relations: Adverse effects from changes in U.S. or international trade policies, including tariffs and trade disputes.
• Sanctions & Export Controls: Compliance requirements and potential business limitations arising from trade restrictions and sanctions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• 12-LOX Inhibition: Focused on developing selective 12-LOX inhibitors, with CAD-1005 as the lead candidate for HIT, and exploring broader applications in diabetes, atherosclerosis, chronic vascular inflammation, and hyper-inflammatory responses.
• Vitamin K Antagonism: Developing tecarfarin as a novel VKA designed to overcome metabolic challenges associated with warfarin, targeting patients with kidney dysfunction or LVADs.
• Factor XIa Inhibition: Advancing frunexian as a first-in-class IV Factor XIa inhibitor for acute care settings, with a focus on contact activation of coagulation by medical devices.

Innovation Pipeline:

• CAD-1005: Planned Phase 3 pivotal trial for HIT. The 12-LOX portfolio also includes second-generation oral candidates (CAD-2000 series) in early development for chronic conditions.
• Tecarfarin: Evaluating opportunities for additional Phase 2/3 trials for ESKD patients with atrial fibrillation and/or stable LVAD patients.
• Frunexian: Phase 2-ready IV Factor XIa inhibitor. The acquired eXIthera assets also include oral Factor XIa inhibitors (EP-7327).

Intellectual Property Portfolio:

• Patent Strategy:
  • CAD-1005 (12-LOX inhibitors): Holds U.S. and foreign patents and applications covering compositions of matter, intravenous formulations (expiring 2034), and methods of treatment. Oral formulation applications are expected to expire in 2043. Additional patent applications are pending for new disease indications, aqueous formulations, dosing protocols, oral formulations, and secondary compounds.
  • Tecarfarin: Filed an international patent application for use in patients with cardiac device implantation and U.S. provisional patent applications for additional uses. However, its two issued U.S. patents (composition of matter and method of treatment) expired in April 2024, and foreign patents expired in April 2025. Future protection relies on potential ODD marketing exclusivity and other market/data exclusivity.
  • Frunexian (Factor XIa inhibitors): Holds five U.S. patents and twelve foreign patents for the intravenous formulation (compositions of matter and methods of treatment), expiring in 2035. Two U.S. patents and three foreign patents for the oral formulation expire in 2039. Additional patent applications are pending for manufacturing methods, solid dosage forms, and pharmaceutical formulations.
• Licensing Programs:
  • Exclusive worldwide license from Old Dominion University for 12-LOX (CAD-1005).
  • Exclusive license agreement with Sichuan Haisco Pharmaceutical Co., Ltd. for the development and commercialization of frunexian in China.
• IP Litigation: Not currently involved in material legal proceedings, but acknowledges the inherent risk of intellectual property litigation in the pharmaceutical industry.

Technology Partnerships:

• Strategic Alliances: Old Dominion University (licensor for CAD-1005), Sichuan Haisco Pharmaceutical Co., Ltd. (licensee for frunexian in China), and Abbott Global Enterprises Limited (collaboration for tecarfarin development).
• Research Collaborations: Not explicitly detailed beyond the aforementioned partnerships.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Board of Directors is classified into three groups, with directors serving staggered three-year terms, which may delay or prevent changes in management or control. Executive officers serve at the discretion of the Board. The company acknowledges the risk of failing to attract and retain senior management and key scientific personnel.

Board Composition: The Board of Directors consists of five members: Quang X. Pham, Lee Golden (Class I); John Murphy, Glynn Wilson (Class II); and Steven Zelenkofske (Class III). John R. Murphy, Dr. Steven Zelenkofske, Dr. Glynn Wilson, and Dr. Lee Golden are deemed independent directors. The Board has established an Audit Committee (Chair: John Murphy, who is an audit committee financial expert), a Compensation Committee (Chair: Dr. Steven Zelenkofske), a Nominating and Corporate Governance Committee (Chair: Dr. Glynn Wilson), and a Science and Technology Committee (Chair: Dr. Steven Zelenkofske).

Human Capital Strategy

Workforce Composition (as of March 27, 2025):

• Total Employees: 5 (all full-time).
• Geographic Distribution: Not explicitly detailed beyond corporate headquarters in Ponte Vedra, Florida.
• Skill Mix: The company also engages approximately 35 consultants and contractors, supplementing its small employee base with specialized expertise.

Talent Management: Acquisition & Retention: The company anticipates the need to significantly increase the size of its organization, including hiring additional managerial, operational, finance, and experienced marketing and sales representatives, as it expands clinical development and commercial activities. Competition for qualified personnel in the pharmaceutical field is intense.

• Employee Value Proposition: Not explicitly detailed.

Diversity & Development:

• Diversity Metrics: Not disclosed.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Cadrenal Therapeutics, Inc.'s product development and marketing activities are subject to extensive regulation by various government authorities, including the FDA in the United States and comparable regulatory authorities in other countries (e.g., EMA in the European Union). This regulation covers the design, research, clinical and non-clinical development, testing, manufacturing, storage, distribution, import, export, labeling, advertising, and marketing of pharmaceutical products. Key regulatory pathways and considerations include:

• FDA Approval Process: Requires submission of Investigational New Drug ("IND") applications, adequate and well-controlled clinical trials (Phase 1, 2, 3) to establish safety and effectiveness, and New Drug Applications ("NDAs") for marketing approval.
• Post-Marketing Requirements: Ongoing surveillance, cGMP compliance, adverse event reporting, product sampling and distribution requirements, and adherence to promotion and advertising regulations.
• Orphan Drug Designation: CAD-1005 and tecarfarin have received ODD from the FDA, potentially granting a seven-year exclusive marketing period in the U.S. for the designated indication, along with other incentives. CAD-1005 also has orphan designation from the EMA.
• Fast Track Designation: CAD-1005 and tecarfarin have received FDA Fast Track designation, intended to facilitate development and expedite review for serious conditions with unmet medical needs.
• Accelerated Approval: The company may pursue accelerated approval pathways, which allow early approval based on surrogate or intermediate clinical endpoints but require post-approval confirmatory trials.
• Pediatric Research Equity Act ("PREA"): Requires data for pediatric subpopulations, with potential for waivers or deferrals.
• Healthcare Fraud and Abuse Laws: Subject to federal and state anti-kickback statutes, false claims laws, the Physician Payments Sunshine Act, and HIPAA, which impact marketing, sales, and business arrangements.
• Animal Welfare Act ("AWA"): Compliance with regulations regarding the humane treatment of animals used in research.

Trade & Export Controls: The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations ("Trade Laws"), which prohibit corrupt or improper payments. Violations can result in substantial penalties and reputational harm.

Legal Proceedings: Cadrenal Therapeutics, Inc. is not currently a party to any material legal proceedings. However, it may face various claims in the ordinary course of business, including those related to intellectual property rights, employment matters, or product safety/efficacy.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company's provision for income taxes is $0, primarily due to federal and state statutory income tax rates on current-year losses being fully offset by a valuation allowance.
• Net Operating Loss Carryforwards: As of December 31, 2025, the company has approximately $23.3 million in federal net operating loss ("NOL") carryforwards and $15.9 million in state NOL carryforwards available to reduce future taxable income. These NOLs can be carried forward indefinitely but are subject to an 80% taxable income deduction limit when utilized.
• Valuation Allowance: A full valuation allowance has been established against net deferred tax assets due to the uncertainty of their realization, which increased by approximately $3.2 million in 2025, primarily due to increased NOLs and capitalized research costs.
• Uncertain Tax Positions: As of December 31, 2025, the company did not have any significant uncertain tax positions and no accrued interest or penalties related to such positions.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Cadrenal Therapeutics, Inc. maintains product liability insurance covering its marketed products and clinical trials. It also carries a directors and officers liability insurance policy.
• Risk Transfer Mechanisms: The company has entered into indemnification agreements with its officers and directors, which provide indemnification to the fullest extent permitted by Delaware law, and its amended and restated bylaws also include indemnification provisions. These measures are intended to attract and retain qualified personnel and mitigate certain liabilities.